Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

NCT02358889 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization
Age-related Macular Degeneration

Interventions

BIOLOGICAL: hI-con1
BIOLOGICAL: ranibizumab
OTHER: Sham injection

Sponsor

Iconic Therapeutics, Inc.